News und Analysen

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at

Electronic Arts Inc. (NASDAQ: EA) will release its financial results for the fiscal quarter and fiscal year ended March 31, 2025 after the close of market on Tuesday, May 6, 2025. In conjunction

Fifth Third Bancorp (Nasdaq: FITB) has announced that preliminary results from the Annual Shareholders Meeting held earlier today have indicated the following directors were re-elected:

• 
  Nicholas

Altria Group, Inc. (Altria) (NYSE: MO) will host a live audio webcast on Tuesday, April 29, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 first-quarter business results. Altria will issue a

TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) has signed an agreement (HoA) with Energia Natural Dominicana (ENADOM), the Joint Venture between AES Dominicana and Energas in the Dominican

TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) has signed a Sales and Purchase Agreement (SPA) with NextDecade to buy 1.5 million tons per annum (Mtpa) of liquefied natural gas (LNG) from the

IFF (NYSE:IFF) today announced that it will release its first quarter 2025 earnings results following the market close on Tuesday, May 6, 2025. The management team will host a live webcast on

Eastman has been recognized as a 4 Star Employer in the 2025 VETS Indexes Employer Awards. The award recognizes Eastman for its strong commitment to recruiting, hiring, retaining, developing and

FICO (NYSE: FICO):

Highlights:

• 
  FICO® World will showcase speakers from more than 50 companies, sharing their successful strategies for using AI and applied intelligence to forge stronger

Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced it has appointed Karen Dykstra to its Board of Directors, effective today

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated